MYREXIS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.01 USD | 0.00% |
|
0.00% | +53.85% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2012 | - | Sales 2013 | - | Capitalization | 2.59M 3.52M |
|---|---|---|---|---|---|
| Net income 2012 | -31M -42.23M | Net income 2013 | -11M -14.98M | EV / Sales 2012 | - |
| Net cash position 2012 | 89.38 121.75 | Net cash position 2013 | 1.21 1.65 | EV / Sales 2013 | - |
| P/E ratio 2012 |
-2.21
x | P/E ratio 2013 |
-0.19
x | Employees | 1 |
| Yield 2012 * |
-
| Yield 2013 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| Current month | -4.76% | ||
| 1 month | -4.76% | ||
| 6 months | +81.82% | ||
| Current year | +53.85% |
1 week
0.01
0.01
1 month
0.010.01
Current year
0.000.01
1 year
0.000.02
3 years
0.000.07
5 years
0.000.08
10 years
0.000.20
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 13-01-21 | |
Gary S. Mather
PRN | Corporate Officer/Principal | - | 00-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 13-01-21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-15 | 0.01 | 0.00% | 401 |
| 24-05-09 | 0.01 | 0.00% | 10,000 |
Delayed Quote OTC Markets, May 15, 2024 at 03:02 pm
More quotes
Myrexi, Inc. is a development-stage company. The Company was a biopharmaceutical company that generated a pipeline of differentiated drug candidates in oncology and autoimmune diseases. In February 2012, it announced that the Company has suspended development activity on all of its preclinical and clinical programs and retained Stifel Nicolaus Weisel, an investment banking firm, to assist in reviewing and evaluating a full range of strategic alternatives to enhance shareholder value. The Company determines to pursue the acquisition of one or more commercial-stage biopharmaceutical assets, with the goal of building a commercial-stage biopharmaceutical company. The Company operates in pharmaceutical development and related research activities. The Companyâs revenues were derived from research performed in the United States and, all of the Companyâs long-lived assets are located in the United States.
| 1st Jan change | Capi. | |
|---|---|---|
| +53.85% | 345K | |
| +7.52% | 113B | |
| +11.38% | 106B | |
| +0.79% | 22.27B | |
| -12.64% | 22.22B | |
| -4.59% | 19.43B | |
| -37.85% | 17.87B | |
| -8.58% | 17.24B | |
| +7.77% | 14.29B | |
| +37.41% | 12.52B |
- Stock Market
- Equities
- MYRX Stock